Squarepoint Ops LLC Has $5.33 Million Holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)

Squarepoint Ops LLC boosted its holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) by 84.8% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 166,962 shares of the company's stock after acquiring an additional 76,621 shares during the period. Squarepoint Ops LLC owned about 0.13% of Apellis Pharmaceuticals worth $5,328,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in APLS. Boxer Capital Management LLC acquired a new stake in Apellis Pharmaceuticals in the fourth quarter worth about $45,504,000. National Bank of Canada FI lifted its stake in shares of Apellis Pharmaceuticals by 266,361.5% in the 4th quarter. National Bank of Canada FI now owns 1,385,600 shares of the company's stock worth $44,214,000 after acquiring an additional 1,385,080 shares during the period. Royal Bank of Canada lifted its stake in shares of Apellis Pharmaceuticals by 969.6% in the 4th quarter. Royal Bank of Canada now owns 1,518,827 shares of the company's stock worth $48,465,000 after acquiring an additional 1,376,832 shares during the period. Cibc World Markets Corp bought a new position in shares of Apellis Pharmaceuticals in the fourth quarter valued at approximately $41,014,000. Finally, Point72 Asset Management L.P. acquired a new position in shares of Apellis Pharmaceuticals during the fourth quarter valued at approximately $40,461,000. Institutional investors own 96.29% of the company's stock.

Apellis Pharmaceuticals Stock Down 2.1%

Apellis Pharmaceuticals stock traded down $0.37 during mid-day trading on Friday, hitting $17.05. The company's stock had a trading volume of 309,601 shares, compared to its average volume of 2,268,429. The firm's 50 day moving average is $19.05 and its 200 day moving average is $26.02. The company has a market cap of $2.14 billion, a PE ratio of -8.40 and a beta of 0.73. The company has a debt-to-equity ratio of 1.91, a current ratio of 4.36 and a quick ratio of 3.73. Apellis Pharmaceuticals, Inc. has a 52-week low of $16.10 and a 52-week high of $43.76.

Apellis Pharmaceuticals (NASDAQ:APLS - Get Free Report) last issued its earnings results on Wednesday, May 7th. The company reported ($0.74) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.36) by ($0.38). The company had revenue of $149.90 million for the quarter, compared to analyst estimates of $197.61 million. Apellis Pharmaceuticals had a negative net margin of 34.97% and a negative return on equity of 103.11%. The company's quarterly revenue was down 3.2% on a year-over-year basis. During the same period last year, the business earned ($0.54) EPS. On average, analysts anticipate that Apellis Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

Insider Buying and Selling at Apellis Pharmaceuticals

In other Apellis Pharmaceuticals news, General Counsel David O. Watson sold 5,569 shares of Apellis Pharmaceuticals stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of $25.10, for a total transaction of $139,781.90. Following the completion of the sale, the general counsel now owns 138,730 shares of the company's stock, valued at $3,482,123. This trade represents a 3.86% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Company insiders own 6.50% of the company's stock.

Wall Street Analysts Forecast Growth

APLS has been the topic of a number of research analyst reports. Robert W. Baird lowered their target price on Apellis Pharmaceuticals from $55.00 to $47.00 and set an "outperform" rating on the stock in a report on Thursday, May 8th. JPMorgan Chase & Co. boosted their target price on shares of Apellis Pharmaceuticals from $50.00 to $54.00 and gave the stock an "overweight" rating in a report on Tuesday, March 4th. Royal Bank of Canada cut their target price on shares of Apellis Pharmaceuticals from $21.00 to $18.00 and set a "sector perform" rating for the company in a research note on Thursday, May 8th. Raymond James lowered shares of Apellis Pharmaceuticals from a "strong-buy" rating to an "outperform" rating and decreased their price target for the stock from $75.00 to $52.00 in a research report on Friday, May 9th. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $57.00 price target on shares of Apellis Pharmaceuticals in a report on Monday, March 3rd. Nine equities research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, Apellis Pharmaceuticals has an average rating of "Moderate Buy" and a consensus target price of $39.89.

Apellis Pharmaceuticals Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).